Article info
PDFEpidemiology
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
- Correspondence to Dr Emanuel Della-Torre, Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; dellatorre.emanuel{at}hsr.it; Professor Lorenzo Dagna, Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; dagna.lorenzo{at}unisr.it
Citation
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Publication history
- Received May 28, 2020
- Revised June 14, 2020
- Accepted June 16, 2020
- First published July 3, 2020.
Online issue publication
September 14, 2020
Article Versions
- Previous version (3 July 2020).
- Previous version (13 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage